1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Incyte Taps Wide-Open Vitiligo Market With Positive Ruxolitinib Results

Phase III Data Could Lead To First Approval

 
• By Alaric DeArment

Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.

Vitiligo on the hands. Shutterstock 1621981522
Incyte reported positive Phase III topline results for topical ruxolitinib in vitiligo • Source: Shutterstock

Incyte Corporation will have a lot of room to grow within a vitiligo market that remains nascent and immature, with little in the way of therapy options for patients, thanks to the positive Phase III results the company announced for a topical formulation of its JAK inhibitor ruxolitinib.

The Wilmington, DE-based company announced 17 May topline results from the Phase III TRuE-V clinical trial program comparing 1.5% ruxolitinib cream against vehicle cream in patients aged 12 and older with vitiligo, though it did not release numerical data

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.